This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ames, M. M. Articles by Moertel, C. G. Search for Related Content PubMed PubMed Citation Articles by Ames, M. M. Articles by Moertel, C. G.

Phase I and Clinical Pharmacological Evaluation of Pirozantrone Hydrochloride (Oxantrazole)¹

Department of Oncology, Mayo Clinic & Foundation, Rochester, Minnesota 55905

Pirozantrone hydrochloride, an anthrapyrazole analogue, was selected for clinical evaluation based on broad antitumor activity against murine tumor systems and on potentially less cardiotoxicity when compared to anthracyclines. This anthrapyrazole analogue is currently under clinical evaluation, and we now report results on a Phase I clinical trial incorporating a pharmacologically guided dose-escalation scheme. Dose escalation was designed to proceed by factors of 2 until the patient drug exposure (concentration x time) was 40% of the murine exposure at the LD₁₀ dose (90 mg/m²). Thereafter, more moderate dose escalations were employed. The target concentration x time value (59 µg-min/ml) derived from preclinical pharmacology data was exceeded in all three patients at a dose of 90 mg/m². A dose of 160 mg/m² was found to reproducibly result in appropriate myelosuppression. This dose is recommended for further testing in Phase II studies. Nonhematological toxicities encountered in this trial were mild, the most notable being phlebitis at the infusion site. Objective responses were observed in two patients, one with metastatic breast cancer and another with metastatic melanoma. Following a 60-min infusion, pirozantrone hydrochloride plasma elimination was monoexponential, with a half-life of approximately 30 min, mean total body clearance of 1.29 liters/min/m², and mean steady state volume of distribution of 29 liters/m².

¹ This work was supported in part by National Cancer Institute Contract CM 57733, DHHS.

² To whom requests for reprints should be addressed, at Department of Oncology, Mayo Clinic & Foundation, 200 First Street S. W., Rochester, MN 55905.

³ Office of Research Resources, Food and Drug Administration, Parklawn 13B21, Rockville, MD, 20857.

Received 12/18/89. Revised 3/ 6/90.

This article has been cited by other articles:

				J. M. Collins Innovations in Phase 1 Trial Design: Where Do We Go Next? Clin. Cancer Res., October 1, 2000; 6(10): 3801 - 3802. [Full Text]

				E. C. Dees, L. R. Whitfield, W. R. Grove, S. Rummel, L. B. Grochow, and R. C. Donehower A Phase I and Pharmacologic Evaluation of the DNA Intercalator CI-958 in Patients with Advanced Solid Tumors Clin. Cancer Res., October 1, 2000; 6(10): 3885 - 3894. [Abstract] [Full Text]